![Company logo of immatics biotechnologies GmbH](http://cdn.pressebox.de/f/22eadb12e790e31e/logos/87413/500_500.gif)
Immatics Announces Full Year 2023 Financial Results and Corporate Update
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous…
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program…
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient…
Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA2…
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target…
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective res…
Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in…
The new course is led by Jacquelyn McMillian-Bohler, an Assistant Clinical Professor at Duke University School of Nursin…
Global Preventive Medicine market is highly fragmented because of existence of multiple members providing these services…